Brief: Briacell Presents Positive Data Demonstrating Survival And Clinical Benefits In Advanced Metastatic Breast Cancer At The 2023 Aacr
17/04/2023 12:47
April 17 (Reuters) - Briacell Therapeutics Corp
BCT.TO :
* BRIACELL PRESENTS POSITIVE DATA DEMONSTRATING SURVIVAL AND
CLINICAL BENEFITS IN ADVANCED METASTATIC BREAST CANCER AT THE
2023 AACR
* BRIACELL THERAPEUTICS - LONGER THAN EXPECTED PATIENT
SURVIVAL
DATA SHOWS TOLERABILITY AND CLINICAL EFFECTIVENESS OF BRIACELL'S
COMBINATION TREATMENT
* BRIACELL THERAPEUTICS CORP - BRIA-IMT™ COMBINATION REGIMEN
ACTIVATED IMMUNE SYSTEM EVEN IN ANERGIC PATIENTS WITH VERY WEAK
IMMUNE SYSTEMS
* BRIACELL THERAPEUTICS CORP - 15 OF 18 PATIENTS REMAIN
ALIVE OF
THOSE RECRUITED SINCE STUDY REOPENED IN 2021
Source text for Eikon: ID:nGNX69WBMn
Further company coverage: BCT.TO
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study